TY - JOUR
TI - Non-gastric extra-nodal marginal zone lymphomas-a single centre
experience on 76 patients
AU - Kalpadakis, Christina
AU - Pangalis, Gerassimos A.
AU - Vassilakopoulos,
AU - Theodoros P.
AU - Kyrtsonis, Maria-Christina
AU - Siakantaris, Marina P.
AU - and Kontopidou, Flora N.
AU - Korkolopoulou, Penelope
AU - Bobotsis,
AU - Panagia
AU - Sahanas, Sotirios
AU - Tzenou, Tatiana
AU - Anagnostou,
AU - Dimitra
AU - Dimitriadou, Evangelia
AU - Yiakoumis, Xanthi
AU - Patsouris,
AU - Evangelos
AU - Roussou, Panagiota
AU - Panayiotidis, Panayiotis and
AU - Papadaki, Eleni
AU - Angelopoulou, Maria K.
JO - Leukemia & Lymphoma
PY - 2008
VL - 49
TODO - 12
SP - 2308-2315
PB - TAYLOR & FRANCIS LTD LONDON
SN - 1042-8194, 1029-2403
TODO - 10.1080/10428190802510331
TODO - MALT; lymphoma; extranodal marginal zone lymphoma
TODO - In the present study, we assessed the clinical and pathological data of
76 patients with the diagnosis of non-gastric extranodal marginal zone
B-cell lymphoma. The most commonly affected sites were salivary glands,
skin, ocular adnexa, lung, intestine and Waldeyer’s ring. Ann Arbor
stage I disease was present in 39 patients (51%), stage II in 10 (13%)
and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at
multiple mucosal sites. Lymph node and bone marrow involvement were
present in 21% and 16%, respectively. Most cases were in the low or
low-intermediate risk group. Treatment was heterogeneous and included
chlorambucil in 59% either alone or in combination with other agents.
Complete and partial remission was achieved in 79% and 7%,
respectively, with an overall response rate of 86%. The 5- and 10-year
overall survival and cause-specific survival rates were 94%, 82% and
95%, 91%, respectively. The 5- and 10-year progression free survival
was 56% and 41%, respectively. The only feature associated with
inferior outcome was disease localisation to the lung.
ER -